抗炭疽芽孢杆菌PagA/保护性抗原参考抗体

Anti-Bacillus anthracis pagA/Protective antigen Reference Antibody

货号：RB9T37015396

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37015396

中文名称
抗炭疽芽孢杆菌PagA/保护性抗原参考抗体

英文名称
Anti-Bacillus anthracis pagA/Protective antigen Reference Antibody

形态
Liquid

纯度
>95% purity as determined by SDS-PAGE.

内毒素水平
Please contact the lab for this information.

应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo

表达系统
Mammalian Cells

登录号
P13423

宿主种属
Chimeric

克隆性
Monoclonal

抗体亚型
IgG1-kappa

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1.5mg/ml

种属反应性
Bacillus anthracis

靶标
Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164

背景信息
Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.

别名
ETI-204, 1351337-07-9

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C for short-term storage (1-2 weeks). Store at -20° C for up to 12 months. For long-

term storage, store at -80° C.

For research use only. Not suitable for clinical or therapeutic use.